SL Science Holding Limited Completes Business Combination with Horizon Space Acquisition II Corp, Listing on Nasdaq

Why It Matters

The financing and Nasdaq debut give SL Science the runway to advance its allogeneic Gamma Delta T platform, positioning it for potential market leadership in solid‑tumor immunotherapies. However, the steep revenue decline and rising losses highlight the short‑term financial pressure of its strategic pivot.

Key Takeaways

• 2025 net revenue fell 35% to $2.2 million after wholesale shift.
• Operating loss widened to $3.8 million as G&A expenses rose 130%.
• $7.8 million PIPE and Nasdaq listing boost financial flexibility for 2026.
• FDA‑active DMF filed for Gamma Delta T platform; IND targeted Q3 2027.
• R&D spending held steady at $2.07 million supporting cell‑therapy pipelines.

Pulse Analysis

SL Science’s 2025 financial release underscores the challenges of transitioning from a high‑frequency retail model to a wholesale distribution framework. While the shift reduced net revenue by $1.17 million, it also lowered cost of goods sold, preserving a modest gross profit margin. The larger story, however, lies in the company’s escalating operating expenses, particularly a 130% jump in general and administrative costs tied to management expansion and the logistical complexities of a public listing. Investors must weigh these short‑term cash drains against the strategic intent to build a scalable, off‑the‑shelf Gamma Delta T cell platform that could disrupt the multi‑billion‑dollar solid‑tumor market.

The capital infusion from a $7.8 million private‑placement PIPE, combined with the Nasdaq Global Market debut, equips SL Science with the liquidity needed to accelerate preclinical work and scale manufacturing. A key milestone is the active FDA Drug Master File for its unmodified Vδ2+ Gamma Delta T technology, signaling regulatory progress that many peers lack. The company’s roadmap targets a pre‑IND meeting for its CD‑19 Armed‑T blood cancer program in early 2027 and an IND filing by Q3 2027, while its GDT platform moves through GLP toxicology studies and CDMO tech‑transfer. These steps aim to position SL Science as a first‑to‑market player in ready‑to‑use allogeneic cell therapies.

From an industry perspective, SL Science’s approach tackles two persistent hurdles in cell therapy: high production costs and lengthy manufacturing timelines. By leveraging an off‑the‑shelf Gamma Delta T cell platform, the firm aspires to deliver scalable treatments for hard‑to‑treat cancers such as pancreatic and brain tumors. If the company can translate its preclinical successes into regulatory approvals and commercial partnerships, it could capture a significant share of the growing immuno‑oncology market. Nonetheless, the path forward hinges on disciplined cash management, successful IND submissions, and the ability to monetize its pipeline amid a competitive landscape.

Deal Summary

On June 12 2026, SL Science Holding Limited completed its business combination with Horizon Space Acquisition II Corp, resulting in the company’s shares beginning to trade on the Nasdaq Global Market under the ticker “SLBT”. The transaction marks the SPAC merger that took the biotech firm public.